REPLICor Inc. To Disclose Late Breaking HBV Clinical Data At American Association for Study of Liver Diseases 2016

NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that the preliminary interim analysis from its latest REP 401 clinical trial has been selected by the American Association for the Study of Liver Disease (AASLD) for presentation during the late-breaking oral abstract session at its annual meeting to be held November 11-15, 2016 in Boston, U.S.A.